ClinVar Miner

Submissions for variant NM_000256.3(MYBPC3):c.1445C>T (p.Ala482Val) (rs370285346)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Laboratory for Molecular Medicine,Partners HealthCare Personalized Medicine RCV000151137 SCV000198920 uncertain significance not specified 2014-07-24 criteria provided, single submitter clinical testing The Ala482Val variant in MYBPC3 has not been previously reported in individuals with cardiomyopathy, but has been identified in 1/8366 European American chromos omes and 2/4082 African American chromosomes by the NHLBI Exome Sequencing Proje ct (http://evs.gs.washington.edu/EVS/). Computational prediction tools and conse rvation analysis suggest that this variant may impact the protein, though this i nformation is not predictive enough to determine pathogenicity. In summary, the clinical significance of the Ala482Val variant is uncertain.
GeneDx RCV000766331 SCV000208364 uncertain significance not provided 2018-02-12 criteria provided, single submitter clinical testing This variant is denoted p.Ala482Val (GCG>GTG): c.1445 C>T in exon 16 of the MYBPC3 gene (NM_000256.3). The A482V variant has not been published as a mutation, nor has it been reported as a benign polymorphism to our knowledge. The NHLBI Exome Sequencing Project reports A482V was observed at a low frequency in individuals of African American ancestry (2/4082 alleles) and European ancestry (1/8366 alleles). The A482V substitution occurs at a position that is conserved across species and in silico analysis predicts this variant is probably damaging to the protein structure/function. Additionally, missense mutations in nearby residues (G490V, G490R, W486G, V471E) have been reported in association with HCM, supporting the functional importance of this region of the protein. However, the A482V variant is a conservative amino acid substitution, which is not likely to impact secondary protein structure as these residues share similar properties. Therefore, based on the currently available information, it is unclear whether this variant is a pathogenic mutation or a rare benign variant. The variant is found in CARDIOMYOPATHY panel(s).
Invitae RCV000475321 SCV000546481 uncertain significance Hypertrophic cardiomyopathy 2018-09-11 criteria provided, single submitter clinical testing This sequence change replaces alanine with valine at codon 482 of the MYBPC3 protein (p.Ala482Val). The alanine residue is highly conserved and there is a small physicochemical difference between alanine and valine. This variant is present in population databases (rs370285346, ExAC 0.02%). This variant has been observed in individuals with hypertrophic cardiomyopathy or dilated cardiomyopathy (PMID: 25351510, Invitae). However, in some of these individuals, pathogenic alleles were also identified in MYBPC3 and TTN respectively, which suggests that this c.1445C>T variant was not the primary cause of disease. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Phosphorus, Inc. RCV000578047 SCV000679773 uncertain significance Left ventricular noncompaction 10 2017-08-01 criteria provided, single submitter clinical testing
Phosphorus, Inc. RCV000578099 SCV000679774 uncertain significance Familial hypertrophic cardiomyopathy 4 2017-08-01 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.